Pharmaceutical Technology

FEBRUARY 25, 2023

According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

XTalks

FEBRUARY 23, 2022

The modular production units are housed in containers that come equipped with raw starting materials and state-of-the-art technology for producing mRNA-based vaccines from start to finish, except for the fill-and-finish step, which will be carried out by local manufacturers.

Life Science 52

Life Science Antibody Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R.

Antibody 52

Antibody DNA Containment Manufacturing 52

Pharmaceutical Technology

APRIL 4, 2023

Merck has secured approval from the US Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for first-line treatment of some adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC).

Antibody 130

Antibody Containment Clinical Development Trials 130

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The 2024 Drugs to Watch, are: 1. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

Drug Discovery World

AUGUST 25, 2023

The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and hopes that existing medications could slow the progression of dementia.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market. Factors driving the demand for injectables.

Marketing 130

Marketing Containment Production Sales 130

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. The Federal Court upheld the Minister’s decision; AbbVie’s appeal of the Federal Court’s decision is pending (Court File No.

Antibody 52

Antibody Production Regulation Marketing 52

Worldwide Clinical Trials

SEPTEMBER 29, 2022

Preclinical assays designed to assess drug toxicity and safety must detect total drug. For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.), Preclinical and clinical PK assay formats serve different goals.

Reagent 130

Reagent Clinical Trials Clinical Trials Antibody 130

Drug Discovery World

DECEMBER 14, 2023

With leading academic institutions and significant recent investment, Glasgow is shaping up to be an important centre for drug discovery and development in the UK. Discoveries in these areas will identify new treatments which will become the cancer drugs of the future.” DDW’s Diana Spencer explores the city’s unique ecosystem.

Drugs 75

Drugs Life Science Research Scientist 75

Drug Discovery World

MARCH 7, 2024

Following closing, the company will have an expanded pipeline that contains multiple assets spanning early and late development stages. The merged pipeline features an antibody-drug conjugate (ADC) toolkit with novel payload and linker technologies.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity. The process eliminates the disadvantages of conventional drying methods or freezing.

Manufacturing 147

Manufacturing Production Containment Antibody 147

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent. About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 28, 2021

An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer – will get underway in the UK next year. Glioblastoma cells have been shown to have receptors to cannabinoids on their cell surface, and lab studies suggest cannabinoid drugs may slow tumour growth.

Trials 135

Trials Drugs Clinical Trials Clinical Trials 135

Drug Discovery World

MARCH 13, 2024

They compared the newer monovalent Covid-19 vaccine, which specifically targets the XBB variant of Omicron (as recommended by the World Health Organisation), with older bivalent vaccines containing a mix of an Omicron variant and the original strain of Covid-19, which the UK deployed in Autumn 2023 before turning to monovalent vaccines.

Vaccination 52

Vaccination Vaccine Research Antibody 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. Food and Drug Administration (FDA). This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif. Reese , M.D.,

Antibody 52

Antibody Manufacturing Production Sales 52

Pharmaceutical Technology

JUNE 5, 2023

ITM-11 is a targeted radionuclide therapy, where patients are injected with small amounts of radiopharmaceuticals that contain a targeting molecule, like antibodies or peptides, and a medical radioisotope. The US Food and Drug Administration (FDA) granted ITM-11 a fast track designation in October 2022.

Trials 147

Trials Containment Antibody Manufacturing 147

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. The post Conversations from ESMO Targeted Anticancer Therapies Congress 2024 appeared first on Drug Discovery World (DDW).

RNA 64

RNA In-Vivo In-Vitro DNA 64

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.

RNA 98

RNA Drugs Protein Immune Response 98

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

Delveinsight

JANUARY 22, 2021

The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. Drug-Induced Thrombocytopenia, Gian Paolo Visentin, Chao Yan Liu).

Marketing 65

Marketing Drugs Antibody Compliance 65

pharmaphorum

FEBRUARY 24, 2022

Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development to develop the small-molecule drug azeliragon into a treatment for inflammatory lung diseases, including COVID-19. said Cantex CEO Stephen Marcus.

Licensing 62

Licensing Licensing Development Drugs 62

XTalks

AUGUST 16, 2022

The vaccine, known as mRNA-1273.214 or Spikevax Bivalent Original/Omicron, is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1). Additionally, the vaccine elicited robust neutralizing antibody responses against the Omicron subvariants BA.4

Vaccination 98

Vaccination Vaccine Antibody Regulation 98

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

XTalks

JULY 14, 2021

In this episode, Ayesha talks about Nestlé’s marketing of Seres Therapeutics’ oral microbiome drug for recurrent C. Seres’ microbiome drug SER-109 aims to restore the healthy bacteria via an oral capsule that contains a protective species of gut bacteria. Nestlé to Market Seres’ Oral Microbiome Drug for C.

Bacteria 52

Bacteria Marketing Drugs Containment 52

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. In principle, these compounds can achieve the fine balance required of modern drugs.

Drugs 40

Drugs Bioavailability Protein Research 40

Roots Analysis

OCTOBER 24, 2023

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.

Manufacturing 40

Manufacturing Hormones Contamination Contract Manufacturing 40

Delveinsight

OCTOBER 1, 2021

This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. The current Myasthenia Gravis therapeutics market has many FDA-approved drugs for the treatment of Myasthenia Gravis.

Marketing 85

Marketing Antibody Drugs Sales 85

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

Pharmaceutical Technology

DECEMBER 9, 2022

Our comprehensive analytical testing portfolio integrates a broad range of capabilities spanning all stages of drug discovery, development and manufacturing. Solvias is well equipped to provide stability testing for all stages of drug development. Integrated analytical services for pharmaceuticals. Quality control release testing.

Development 130

Development Manufacturing Production Vaccination 130

Pharmaceutical Technology

JULY 29, 2022

This data has been shared with regulators, including the US Food and Drug Administration (FDA), and a request for US Emergency Use Authorisation (EUA) is planned. The booster dose elicited a significantly higher neutralising antibody response against Omicron subvariants BA.4 1 sub-lineage on 19 July.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

The Pharma Data

JANUARY 4, 2021

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. MARSEILLE, France, Jan. MARSEILLE, France, Jan. Cell 2019 ).

Development 52

Development Antibody Drugs Containment 52